GET A VALUABLE CERTIFICATE FOR JOB MARKET


ACADEMIC RECOGNITION OF 3 OR 6 CREDITS


DESIGNED FOR EXPERTS BY EXPERTS


PRINCIPLES OF PHARMACOECONOMICS AND VALUATION OF HEALTH STATES


OBJECTIVES



Economic considerations play an important role in decision-making on medicines, e.g. for pricing and reimbursement purposes. Insight in the strengths and weaknesses of the different economic evaluation techniques is needed for improved decision making on medicines.

The objective of this module is to gain insight into different preference valuation techniques and (pharmaco)economic evaluation methods.

At the end of this module, trainees will be able to:

describe the elements and scope of Health Technology Assessment (HTA)

execute a cost study and how to take into account the perspective in such studies

calculate the different effect measures used in pharmacoeconomics

describe the different approaches for valuation of health states and to interpret these values

conduct a pharmacoeconomic analysis including all relevant aspects(incremental cost-effectiveness ratio (ICER), type of outcome analysis including differential timing, health outcomes models, and sensitivity analysis)

evaluate the quality of a pharmacoeconomic evaluation study

design a pharmacoeconomic study (extended version)

Pharmacoeconomics, cost-effectiveness, cost-utility, cost-benefit, health state valuation

 

MODULE PARTS



  1. Introduction
  2. Costs
  3. Effects
  4. Pharmacoeconomic analysis
  5. How to perform a good pharmacoeconomic evaluation

 

TRAINER TEAM



Coordinator: Dr Jet Van Der Zijden (from Utrecht Universiteit)

Expert(s): Prof Olaf Klungel, Dr Anke Hovels, Dr Geert Frederix, Dr Rob Hermans, Armina Padmasawitri, Joost Geenen (from Utrecht Universiteit), Dr Pearl Gumbs (from Nutricia), Dr George Quartey (from F. Hoffmann-La Roche Ltd), Dr Hans Tamminga (from GlaxoSmithKline Research and Development Ltd).

Intermediate level
75 h workload over 3 months (3 ECTS credits)
NB: An extended version (6 ECTS credits) of this module is mandatory for Master students choosing the specialisation track #3 "Medicines benefit-risk assessment"
Key dates
Course calendar
Certificate award
or included in Master Year 2 or PhD programme
English language
Online based learning
Student: 1,500 €
Professional: 3,000 €
  Savings could be offered under eligibility conditions.

APPLY NOW

Applications open until December 08th, 2017

Or include this module in your training curriculum choices...

Master Year 2 PhD



Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners